Generic Medicine Info
Indications and Dosage
Benign prostatic hyperplasia
Adult: For the treatment of urinary outflow obstruction: Initially, 20 mg bid, may be increased, if necessary, in increments of 20 mg at 2-week intervals. Max: 100 mg daily in divided doses.
Elderly: 20 mg daily may be sufficient. Doses to be given at night.

Adult: Initially, 25 mg bid, may be increased, if necessary, in increments of 25-50 mg daily at 2-week intervals. Max: 200 mg daily in 2-3 divided doses.
Known heart failure. Concomitant use with MAOIs.
Special Precautions
Patient with history of depression, epilepsy, Parkinson's disease. Patient undergoing cataract surgery. Renal and hepatic impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: CNS effects (e.g. drowsiness, sedation), extrapyramidal reactions.
Gastrointestinal disorders: Nausea, diarrhoea, xerostomia.
General disorders and administration site conditions: Fatigue.
Investigations: Weight gain.
Nervous system disorders: Headache.
Psychiatric disorders: Depression.
Reproductive system and breast disorders: Ejaculation failure.
Respiratory, thoracic and mediastinal disorders: Nasal congestion.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Hypotension with or without syncope (including postural hypotension).
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure.
Symptoms: Deep sedation leading to coma; fits, and hypotension. Management: Symptomatic and supportive treatment. Perform gastric lavage; may administer activated charcoal or a dose of ipecacuanha in case of recent ingestion. Initiate cardiac monitoring immediately and for at least 24 hours. Monitor and assist ventilation, if needed. Maintain circulatory support and control hypotension. Closely monitor temperature; carry out rewarming in case of hypothermia to avoid possible convulsions. Diazepam may be given if convulsion occurs.
Drug Interactions
Enhanced hypotensive effects with antihypertensives, diuretics, antidepressants, anxiolytics, hypnotics and moxisylyte.
Potentially Fatal: Enhanced hypotensive effect with MAOIs.
Food Interaction
Increased rate and extent of absorption with alcohol.
Mechanism of Action: Indoramin is an α-adrenoceptor blocking agent which decreases peripheral resistance and blood pressure and relaxes the hyperplastic muscle in the prostate by selectively and competitively inhibiting postsynaptic α1-adrenoceptors. Its actions are similar to those of prazosin. Additionally, it has also been reported to possess membrane-stabilising properties and competitive antagonism activity at histamine H1 and 5-hydroxytryptamine receptors.
Absorption: Readily and rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1-2 hours.
Distribution: Plasma protein binding: >90%.
Metabolism: Extensively metabolised and undergoes first-pass metabolism.
Excretion: Via faeces (46%); urine (35%). Elimination half-life: 5 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 33625, Indoramin. Accessed Oct. 25, 2023.

Store below 25°C.
MIMS Class
Other Antihypertensives
ATC Classification
C02CA02 - indoramin ; Belongs to the class of alpha-adrenoreceptor antagonists, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.
Anon. Indoramin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 31/07/2023.

Buckingham R (ed). Indoramin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 31/07/2023.

Doralese Tiltab Tablets 20 mg (Chemidex Pharma Ltd.). MHRA. Accessed 31/07/2023.

Indoramin 20 mg Film-coated Tablets (Generics [UK] Ltd t/a Mylan). MHRA. Accessed 31/07/2023.

Joint Formulary Committee. Indoramin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 31/07/2023.

Disclaimer: This information is independently developed by MIMS based on Indoramin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in